Sanofi top pharmaceutical products 2017-2019

Lantus was Sanofi’s best-selling pharmaceutical product in 2019 according to the company’s latest annual financial report. The long-acting insulin (glargine), used to treat diabetes type I and II, generated some three billion U.S. dollars worldwide. Lantus has been among the company’s top products for many years but has shown significant decrease in revenue since the patent expired during 2015. In 2016, Sanofi introduced a much more potent formulation of insulin glargine under the brand name Toujeo.

Diabetes treatment

Diabetes is one of the most prevalent chronic diseases worldwide. Accordingly, antidiabetics form one of the three largest therapy classes within the global pharmaceutical market. Diabetes means that the human body is not able to produce its own insulin or use its insulin effectively. While persons with type 1 diabetes always need insulin for treatment, diabetes type 2 patients do not necessarily need it. A key medicine for persons with type 2 diabetes is metformin which helps to control blood sugar and to use insulin effectively. Change in lifestyle, a balanced diet, and physical activity might also be important parts of diabetes treatment.

The diabetes market

As mentioned, the diabetes segment is one of the largest single therapy classes within the pharmaceutical market, generating over 78 billion U.S. dollars in 2018 worldwide. With projected increasing numbers of people affected worldwide until 2045, the diabetes market is also expected to grow. Currently, French company Sanofi is the world’s second largest antidiabetics manufacturing company based on revenue, only topped by Danish company Novo Nordisk. It is expected that Novo Nordisk will extend its market share in the diabetes sector up to 35 percent until 2024, thus maintaining the global leading position.

Sanofi's selected top pharmaceutical products based on revenue from 2017 to 2019

Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

$39 $59 per month *
in the first 12 months
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$468 / Year

Show detailed source information?
Register for free
Already a member?
Log in

Release date

March 2020



Survey time period

2017 to 2019

Supplementary notes

This statistic was assembled from several financial reports.

Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.

Statistics on "Sanofi"

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.